These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 27091753)

  • 1. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
    Canton R; Morrissey I; Vila J; Tato M; García-Castillo M; López Y; Gargallo-Viola D; Zsolt I
    Future Microbiol; 2018 May; 13():3-19. PubMed ID: 29745242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of ozenoxacin and other antimicrobials against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020.
    Kurokawa I; Kanayama S; Yamasaki O
    J Infect Chemother; 2022 Dec; 28(12):1693-1696. PubMed ID: 35988886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
    Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris.
    Nakajima A; Ikeda F; Kanayama S; Okamoto K; Matsumoto T; Ishii R; Fujikawa A; Takei K; Kawashima M
    J Med Microbiol; 2016 Aug; 65(8):745-750. PubMed ID: 27305898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18).
    Zhanel GG; Adam HJ; Baxter M; Lagace-Wiens PRS; Karlowsky JA
    J Antimicrob Chemother; 2021 Jun; 76(7):1808-1814. PubMed ID: 33792700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
    Kanayama S; Okamoto K; Ikeda F; Ishii R; Matsumoto T; Hayashi N; Gotoh N
    J Infect Chemother; 2017 Jun; 23(6):374-380. PubMed ID: 28389164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical Ozenoxacin Cream 1% for Impetigo: A Review.
    Schachner L; Andriessen A; Bhatia N; Grada A; Patele D
    J Drugs Dermatol; 2019 Jul; 18(7):655-661. PubMed ID: 31334625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS; Flamm RK; Farrell DJ; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    García-Castillo M; Hernández-García M; Correa A; Coppi M; Griener T; Fritsche T; Pitart C; Sampaio J; Seifert H; Wake K; Wootton M; Vila J; Cantón R
    JAC Antimicrob Resist; 2024 Jun; 6(3):dlae088. PubMed ID: 38872714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    J Antimicrob Chemother; 2015 Jan; 70(1):57-61. PubMed ID: 25261416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
    Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.
    Sader HS; Mendes RE; Streit JM; Flamm RK
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    PLoS One; 2019; 14(10):e0223326. PubMed ID: 31596898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
    Yamakawa T; Mitsuyama J; Hayashi K
    J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
    Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
    J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of eight fluoroquinolones against both methicillin-susceptible and -resistant Staphylococcus aureus isolated from skin infections.
    Nishijima S; Namura S; Akamatsu H; Kawai S; Asada Y; Kawabata S; Fujita M
    J Dermatol; 1995 Feb; 22(2):153-5. PubMed ID: 7722093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.